


Closing remarks

Innovation & Growth: Progress with strategy

Pascal Soriot, Executive Director, Chief Executive Officer



Completing the first phase of the journey



2012-2014

Building strong foundations

2015-2017

Delivering on return to growth

2018+

Sustainable delivery and growth



Key messages

- ✓ Strategy implementation on track
- ✓ Building a sustainable, durable and more profitable business
- ✓ Pipeline value rapidly increasing
- ✓ Accelerating return to growth and ambition to become a >\$45bn company by 2023



AstraZeneca: A biopharmaceuticals leader

Science-based biopharmaceuticals leader in 3 core therapeutic areas

Productive R&D

- ✓ Platform of small molecules & biologics
- Sustainable model & early pipeline
- ✓ Growing late-stage; strength in IO*
- Growing focus on devices & diagnostics

Strong business

- Stable business of established products
- Global scale; emerging market strength
- 6 platforms driving growth towards a balance of primary and specialty care

Sustainable organisation


- ✓ Innovative, entrepreneurial culture
- ✓ Strong talent base
- Simple and productive organisation

Disciplined capital allocation

Commitment to progressive dividend



^{*} IO = Immuno-oncology



Closing remarks

Innovation & Growth: Progress with strategy

Pascal Soriot, Executive Director, Chief Executive Officer